Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response

被引:240
作者
Polyak, SJ
Khabar, KSA
Paschal, DM
Ezelle, HJ
Duverlie, G
Barber, GN
Levy, DE
Mukaida, N
Gretch, DR
机构
[1] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[2] King Faisal Specialist Hosp & Res Ctr, Dept Biol, Riyadh 11211, Saudi Arabia
[3] King Faisal Specialist Hosp & Res Ctr, Dept Med Res, Riyadh 11211, Saudi Arabia
[4] Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL USA
[5] CHU Amiens, Hop Sud, Dept Virol, Amiens, France
[6] NYU, Sch Med, Dept Pathol, New York, NY USA
[7] Kanazawa Univ, Dept Mol Oncol, Kanazawa, Ishikawa 920, Japan
关键词
D O I
10.1128/JVI.75.13.6095-6106.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Hepatitis C virus (HCV), a major cause of liver disease worldwide, is frequently resistant to the antiviral alpha interferon (IFN). The HCV nonstructural 5A (NS5A) protein has been implicated in HCV antiviral resistance in many studies. NS5A antagonizes the IFN antiviral response in vitro, and one mechanism is via inhibition of a key IFN-induced enzyme, the double-stranded-RNA-activated protein kinase (PKR), In the present study we determined if NS5A uses other strategies to subvert the IFN system. Expression of full-length NS5A proteins from patients who exhibited a complete response (FL-NS5A-CR) or were nonresponsive (FL-NS5A-NR) to IFN therapy in HeLa cells had no effect on IFN induction of IFN-stimulated gene factor 3 (ISGF-3). Expression of mutant NS5A proteins lacking 110 (NS5A-Delta N110), 222 (NS5A-Delta N222), and 334 amino-terminal amino acids and mutants lacking 117 and 230 carboxy-terminal amino acids also had no effect on ISGF-3 induction by IFN, Expression of FL-NS5A-CR and FL-NS5A-NR did not affect IFN-induced STAT-1 tyrosine phosphorylation or upregulation of PKR and major histocompatibility complex class I antigens, However, NS5A expression in human cells induced interleukin 8 (IL-8) mRNA and protein, and this effect correlated with inhibition of the antiviral effects of IFN in an in vitro bioassay, NS5A induced transcription of a reporter gene driven by the IL-8 promoter, and the first 133 bp of the IL-8 promoter made up the minimal domain required for NS5A transactivation, NSSA-Delta N110 and NS5A-Delta N222 stimulated the 1L-8 promoter to higher levels than did the full-length NS5A protein, and this correlated with increased nuclear localization of the proteins, Additional mutagenesis of the IL-8 promoter suggested that NF-kappaB and AP-1 were important in NS5A-Delta N222 transactivation in the presence of tumor necrosis factor alpha and that NF-IL-6 was inhibitory to this process. This study suggests that NS5A inhibits the antiviral actions of IFN by at least two mechanisms and provides the first evidence for a biological effect of the transcriptional activity of the NS5A protein. During HCV infection, viral proteins may induce chemokines that contribute to HCV antiviral resistance and pathogenesis.
引用
收藏
页码:6095 / 6106
页数:12
相关论文
共 82 条
[1]  
Abid K, 2000, Science, V287, P1555
[2]   TYPE-I INTERFERONS ARE POTENT INHIBITORS OF INTERLEUKIN-8 PRODUCTION IN HEMATOPOIETIC AND BONE-MARROW STROMAL CELLS [J].
AMAN, MJ ;
RUDOLF, G ;
GOLDSCHMITT, J ;
AULITZKY, WE ;
LAM, C ;
HUBER, C ;
PESCHEL, C .
BLOOD, 1993, 82 (08) :2371-2378
[3]   Efficient initiation of HCV RNA replication in cell culture [J].
Blight, KJ ;
Kolykhalov, AA ;
Rice, CM .
SCIENCE, 2000, 290 (5498) :1972-1974
[4]   Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials [J].
Carithers, RL ;
Emerson, SS .
HEPATOLOGY, 1997, 26 (03) :S83-S88
[5]   THE E3L GENE OF VACCINIA VIRUS ENCODES AN INHIBITOR OF THE INTERFERON-INDUCED, DOUBLE-STRANDED RNA-DEPENDENT PROTEIN-KINASE [J].
CHANG, HW ;
WATSON, JC ;
JACOBS, BL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (11) :4825-4829
[6]   Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection [J].
Chayama, K ;
Tsubota, A ;
Kobayashi, M ;
Okamoto, K ;
Hashimoto, M ;
Miyano, Y ;
Koike, H ;
Kobayashi, M ;
Koida, I ;
Arase, Y ;
Saitoh, S ;
Suzuki, Y ;
Murashima, N ;
Ikeda, K ;
Kumada, H .
HEPATOLOGY, 1997, 25 (03) :745-749
[7]  
Chung RT, 1999, J MED VIROL, V58, P353, DOI 10.1002/(SICI)1096-9071(199908)58:4&lt
[8]  
353::AID-JMV6&gt
[9]  
3.0.CO
[10]  
2-C